GlassScriptPhysician profile
Matthew J Barth
NPI 1477714103
$43,464.91
in general payments reported to CMS, 2019-2025
17 companies · $22K in 2025
The $22K reported for 2025 was more than what 92% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $3,426 · 2022: $337 · 2023: $263 · 2024: $18K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Consulting Fee: $5,669 · Food and Beverage: $1,055 · Travel and Lodging: $51.78 · Education: $12.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,530.00 |
| Consulting Fee | $5,668.75 |
| Food and Beverage | $1,055.43 |
| Travel and Lodging | $51.78 |
| Education | $12.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $32,695.89 | 2019-2025 | Koselugo, Strensiq, Ultomiris |
| Springworks Therapeutics, INC. | $4,289.03 | 2024-2025 | Gomekli |
| Astrazeneca Pharmaceuticals LP | $3,425.50 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,541.25 | 2025 | |
| Genzyme Corporation | $675.00 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $485.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $83.78 | 2023 | |
| Servier Pharmaceuticals LLC | $57.79 | 2024-2025 | |
| Pfizer INC. | $34.44 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.05 | 2023 | Vpriv |
| Astellas Pharma US INC | $33.22 | 2024 | Cresemba |
| Sobi, INC | $24.85 | 2023 | |
| Ucb, INC. | $23.15 | 2024 | Fintepla |
| Sk Life Science, INC. | $22.72 | 2023 | |
| Syndax Pharmaceuticals, INC. | $19.54 | 2025 | Revuforj |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $18.85 | 2023 | Valtoco |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Barth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.